ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$10.23

Market cap

$624.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.66

Enterprise value

$772.55M

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights

Arcutis Biotherapeutics's gross margin has increased by 26% QoQ

ARQT's EPS is down by 35% YoY but it is up by 4.1% QoQ

Arcutis Biotherapeutics's debt has surged by 161% YoY

Arcutis Biotherapeutics's net income has shrunk by 51% YoY

Sector: Healthcare

Industry: Biotechnology

Website: http://arcutis.com

Peers: OVID

Key stats

What are the main financial stats of ARQT

Market

Shares outstanding

61.08M

Market cap

$624.88M

Enterprise value

$772.55M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.97

Price to sales (P/S)

152.73

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

209.59

Earnings

Revenue

$3.69M

EBIT

-$295.81M

EBITDA

-$294.55M

Free cash flow

-$258.05M

Per share

EPS

-$5.66

Free cash flow per share

-$4.69

Book value per share

$3.44

Revenue per share

$0.07

TBVPS

$8.03

Balance sheet

Total assets

$449.27M

Total liabilities

$239.69M

Debt

$202.54M

Equity

$209.58M

Working capital

$399.6M

Liquidity

Debt to equity

0.97

Current ratio

11.57

Quick ratio

11.09

Net debt/EBITDA

-0.5

Margins

EBITDA margin

-7,991.1%

Gross margin

79.5%

Net margin

-8,449.8%

Operating margin

-8,183%

Efficiency

Return on assets

-76.8%

Return on equity

-134%

Return on invested capital

-67.2%

Return on capital employed

-71.9%

Return on sales

-8,025.1%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time

Intraday

-5.28%

1 week

-7.75%

1 month

-34.67%

1 year

-42.17%

YTD

-30.88%

QTD

-30.88%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time

Revenue

$3.69M

Gross profit

$2.93M

Operating income

-$301.63M

Net income

-$311.46M

Gross margin

79.5%

Net margin

-8,449.8%

The operating margin has soared by 81% from the previous quarter

Arcutis Biotherapeutics's net margin has surged by 80% QoQ

Arcutis Biotherapeutics's net income has shrunk by 51% YoY

The company's operating income fell by 46% YoY

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation

P/E

N/A

P/B

2.97

P/S

152.73

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

209.59

ARQT's EPS is down by 35% YoY but it is up by 4.1% QoQ

The stock's price to book (P/B) is 31% less than its last 4 quarters average of 4.3

Arcutis Biotherapeutics's equity has decreased by 30% YoY and by 23% QoQ

Efficiency

How efficient is Arcutis Biotherapeutics business performance

The ROE has plunged by 148% YoY and by 10% from the previous quarter

ARQT's ROS has soared by 81% QoQ

ARQT's return on assets has dropped by 58% year-on-year but it is up by 2.3% since the previous quarter

The company's return on invested capital rose by 13% QoQ and by 4% YoY

Dividends

What is ARQT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time

ARQT's total assets is 87% greater than its total liabilities

The total liabilities has soared by 117% YoY

Arcutis Biotherapeutics's quick ratio has decreased by 14% QoQ and by 4.9% YoY

Arcutis Biotherapeutics's debt is 3.4% lower than its equity

Arcutis Biotherapeutics's debt has surged by 161% YoY

ARQT's debt to equity is up by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.